Subscribe to Search results

Angus MacPherson wrote a letter to John Harley discussing the results of the shift working trial and outlining that the necessary building works could be completed in approximately two and a half years.

Published on:

Planning was eventually under way for a new building to constitute BPL at Elstree.

Published on:

A meeting of regional transfusion directors was held at BPL to receive information concerning the future requirements for increased supply of plasma for fractionation.

Published on:

A report was published titled "Value of SAG-M Systems in the Provision of Plasma Products".

Published on:

BPL noted that for the first year since Hepatitis B testing had first been carried out none of the five-litre plasma pools screened for Hepatitis B at regional transfusion centres and dispatched to the BPL had tested positive for Hepatitis B.

Published on:

Plasmapheresis grew as a source of plasma and, by 1986/1987, had given rise to just over 10% of the plasma sent to BPL.

Published on:

A new scheme of distribution for NHS Factor 8 concentrates was introduced. The amount to be sent to each region would be calculated by reference to the number of patients who had been reported as being treated in the haemophilia centres of that region in 1974.

Published on:

SAG-M was most likely introduced in September 1982.

Published on:

In Parliament, Dr Owen described the Government's policy as making the NHS self-sufficient in the production of Factor 8 as soon as "practicable".

Published on:

Elstree and Oxford were producing around 15 million international units of Factor 8 and NBTS was producing about the same amount in terms of cryoprecipitate.

Published on:

The additional donations required to meet self-sufficiency targets were calculated after detailed discussions between DHSS and regional transfusion centres. Some regions produced no fresh frozen plasma for factor concentrate at all, whereas Oxford and the North East Thames were producing large quantities.

Published on:

The Medicines Inspectorate began its inspection of BPL and concluded that planning for essential improvements should begin immediately and called for urgent action. It observed the current position was not a recent situation.

Published on:

Following the redevelopment of BPL, an increase in plasma supplies and factor concentrate production occurred.

Published on:

The Northern Regional Health Authority was offered increased capital and the West Midlands Regional Health Authority was offered an increased revenue allocation in order to produce the plasma required.

Published on:

In considering what needs the Department of Health should plan for, a review of blood and blood products in 1976 noted that there was little information to show whether current practices represented optimal use of products or whether figures were misleading due to wasteful practices.

Published on:

Thomas Dutton identified that the customary method of financing the NBTS was not conducive to the development of such a partnership and this was probably the biggest factor that led to the delay in mounting the AHG (Factor 8) concentrate production programme.

Published on:

The introduction of component therapy on a large scale reduced the need for independent, self-sufficient regional units.

Published on:

Thomas Dutton stated that devising and effectively managing a balanced programme for the preparation and distribution of blood components including clotting factors as "probably the most urgent task facing the NBTS" and he spoke of the need to fractionate something approaching one million donations annually.

Published on:

The 1975 target of 350,000 donor units was met, but Thomas Dutton stated that this target had long since been recognised as too low.

Published on:

Thomas Dutton observed that the Development of the NBTS Trends Report essentially said no more about Factor 8 requirements than some experts had been saying for years, which had now become generally accepted.

Published on: